Quick Answer
BioXcel Therapeutics, Inc. reported Earnings Per Share Diluted of $5.73 (loss) per share for the year ending 2025.
- BioXcel Therapeutics, Inc. showed an increase of +75.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $1.08 (loss) per share | Q2 2021: $1.11 (loss) per share | Q3 2021: $0.96 (loss) per share | Q1 2022: $1.12 (loss) per share | Q2 2022: $1.35 (loss) per share | Q3 2022: $1.49 (loss) per share | Q1 2023: $1.84 (loss) per share | Q2 2023: $1.83 (loss) per share | Q3 2023: $1.72 (loss) per share | Q1 2024: $13.89 (loss) per share | Q2 2024: $3.30 (loss) per share | Q3 2024: $5.15 (loss) per share | Q1 2025: $1.50 (loss) per share | Q2 2025: $2.45 (loss) per share | Q3 2025: $2.18 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), BioXcel Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 51.2%.
- Historical annual values: Fiscal year 2025: $5.73 (loss) per share | Fiscal year 2024: $23.51 (loss) per share | Fiscal year 2023: $98.33 (loss) per share | Fiscal year 2022: $5.92 (loss) per share | Fiscal year 2021: $4.05 (loss) per share | Fiscal year 2020: $3.79 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: